Kozo Morimoto

Dr. Kozo Morimoto


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Internal Medicine
Verified
Journal Article
Open access
PDF file
KMKozo Morimoto
Kozo Morimoto
YKYuko Kazumi
Yuko Kazumi
SMShinji Maeda
Shinji Maeda
KYKozo Yoshimori
Kozo Yoshimori
TYTakashi Yoshiyama
Takashi Yoshiyama
SKShoji Kudoh
Shoji Kudoh
The DNA sequencing analyses of the 16S rRNA gene, rpoB and hsp65 were conducted to characterize six strains that had been identified as Mycobacterium xenopi by DNA-DNA hybridization (DDH) for past ten years in our hospital. The results revealed Mycobacterium heckeshornense infection in one of the six cases. A 47-year-old man, who had been treated for pneumonia, had pulmonary nontuberculous mycobacterial disease. The sputa from the patient were culture positive for mycobacterium in three times. And it was diagnosed as M. xenopiby DDH method. Chest X-ray showed fibrocavitary lesion in right upper lobe was successfully treated with clarithromycin for four weeks.

1 December 2022 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
KMKozo Morimoto
Kozo Morimoto
KIKazuro Iwai
Kazuro Iwai
TYTakashi Yoshiyama
Takashi Yoshiyama
MIMasashi Ito
Masashi Ito
FUFumiko Uesugi
Fumiko Uesugi
KOKen Ohta
Ken Ohta
Background: This study assessed longitudinal national data on mortality due to nontuberculous mycobacteriosis (NTMosis) and bronchiectasis and the association between the two diseases.Methods: We analysed the national death statistics of Japan from 1970 to 2015. The International Classification of Disease (ICD) codes were used to extract the relevant data. Crude mortality, age-adjusted mortality and standardised mortality rates were calculated using vital statistics and the population in 2000. We also identified domestic publications related to NTMosis and bronchiectasis with an internet-based search system.Results: The total number of bronchiectasis-related deaths remained at the same level, which was approximately 1000, for 45 years, although the number of deaths has consistently decreased in males but increased in females since the mid-1990s. A substantial increasing trend in females was also observed for NTMosis in the same period. The age-adjusted mortality data showed an increase in mortality in women due to NTMosis and confirmed the trend in bronchiectasis in women. The patterns in the number of domestic reports showed a recent slight increase in bronchiectasis and a marked increase in NTMosis.Conclusions: The trends in bronchiectasis-related mortality differed by sex. The epidemiological trends in the two diseases were associated, especially in elderly females since the mid-1990s. It is suggested that pulmonary NTMosis without pre-existing bronchiectasis might be a leading cause of postinfectious bronchiectasis in Japan.

1 November 2017 in Respiratory Investigation
Verified
Journal Article
Closed access
TFToshihiko Fukuoka
Toshihiko Fukuoka
KMKozo Morimoto
Kozo Morimoto
TOTomoyuki Ogata
Tomoyuki Ogata
KUKazuhiro Uchimura
Kazuhiro Uchimura

1 June 2018 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
SMS. Matsuda
S. Matsuda
SSS. Suzuki
S. Suzuki
KMKozo Morimoto
Kozo Morimoto
AAA. Aono
A. Aono
KNK. Nishio
K. Nishio
HGH. Goto
H. Goto

23 June 2025 in medRxiv
Verified
Preprint
Open access
PDF file
DMDiana Moreira-Sousa
Diana Moreira-Sousa
BMBeatriz Martins
Beatriz Martins
Ana AguiarAna Aguiar
Ana Aguiar
Marina PinheiroMarina Pinheiro
Marina Pinheiro
OAOnno W. Akkerman
Onno W. Akkerman
RDRaquel Duarte
Raquel Duarte
Introduction: Managing patients with nontuberculous mycobacterial pulmonary disease (NTM-PD) unresponsive to guideline-based therapy presents a significant clinical challenge. Limited treatment options and the complex nature of disease progression make therapeutic decision-making difficult. This study systematically reviewed the existing literature on management strategies and emerging therapeutic approaches for refractory NTM-PD. Methods: We systematically reviewed studies on NTM-PD treatment failure published from inception until 31 January 2024, examining associated factors, intensification strategies, and supportive measures. Twenty-five studies met the inclusion criteria, predominantly exhibiting retrospective observational methodology and focusing on pulmonary disease by Mycobacterium avium complex and Mycobacterium abscessus species. Findings were synthesised qualitatively due to the considerable heterogeneity in study design and outcomes. Results: Before treatment intensification or de-escalation, the impact of antibiotic treatment on health-related quality of life and microbiological factors, such as acquired resistance and changes in the pathogenic NTM, should be assessed. The presence of severe radiological findings at the beginning of treatment and a history of multiple antibiotic regimen modifications were associated with a lower chance of treatment success. Evidence regarding supportive interventions for treatment-refractory NTM-PD, such as nutritional counselling, respiratory rehabilitation, and psychosocial support, remains limited. Intermittent administration of intravenous antibiotics may be an additional strategy for symptom management. Depending on the causative NTM species, some antibiotic options have been explored for treatment intensification, although most of these are based on observational studies. Surgical resection remains an option for localised disease, although the risk of recurrence remains substantial in the case of preoperative positive culture. Novel therapeutic approaches remain under investigation as potential alternatives. Discussion: This systematic review underscores the complexity of managing refractory NTM-PD, highlighting the role of treatment intensification, symptom control, supportive measures and knowledge gaps. While no standardised approach exists, individualised strategies incorporating clinical, microbiological, and radiological factors remain essential for optimising patient outcomes.

1 January 2012 in Internal Medicine
Verified
Journal Article
Open access
PDF file
KMKozo Morimoto
Kozo Morimoto
TYTakashi Yoshiyama
Takashi Yoshiyama
MOMasao Okumura
Masao Okumura
YHYoshihiko Hoshino
Yoshihiko Hoshino
KYKozo Yoshimori
Kozo Yoshimori
SKShoji Kudoh
Shoji Kudoh
We herein report two cases of multidrug-resistant tuberculosis (MDR-TB) in patients with a history of pulmonary nontuberculous mycobacteriosis (PNTM). A 50-year-old man was diagnosed with MDR-TB five years after receiving treatment for pulmonary Mycobacterium kansasii infection. In the second patient, a 72-year-old woman, the diagnosis of PNTM was confirmed twice with two bronchial washings; she was diagnosed with MDR-TB 29 months after presenting with PNTM. It is highly possible that these two patients were already infected with tuberculosis (TB) at the time of PNTM diagnosis and acquired resistance to anti-TB drugs as a result of undergoing treatment for PNTM.